Further Information:
The Health Products Regulatory Authority has been notified of a shortage of the following products:
- Actilyse Cathflo 2mg Powder for Solution for Injection and Infusion - PA0775/011/001
- Aminophylline Hydrate 25mg/ml Solution for Injection - PA0073/099/001
- Crinone 8 % w/w Progesterone Gel - PA2286/001/001
- Esomeprazole 40mg Powder for Solution Injection/Infusion - PA2315/132/005
- Flutiform 50mcg/5mcg Per Metered Dose Pressurised Inhalation, Suspension.- PA1688/013/001
- Glycopyrronium bromide 200 micrograms/ml Solution for Injection (3ml presentation only) - PA0857/001/001
- Kopen 250mg Tablets - PA0298/007/001
- MacroBID 100mg Prolonged Release Capsules - PA1142/033/001
- Minims Tetracaine Hydrochloride 1% w/v Eye Drops, Solution - PA22698/020/002
- Oxycontin 20mg Prolonged Release Tablets - PA1688/005/003
- Paracetamol 500mg Tablets - PA2315/065/003
- RoActemra 162mg Solution for Injection in Pre-Filled pen - EU/1/08/492/009-10
- Tambocor 50mg Tablets - PA2010/026/002
- Vancocin Matrigel 125mg Hard Capsules - PA1226/005/001
- Ventolin 500mcg/ml Solution for Injection- PA1077/049/001
The following shortages have been resolved and supply has resumed to the Irish market:
- Adrenaline (Epinephrine) 1 mg/10 ml (1:10,000) Solution for Injection in Pre-Filled Syringe - PA1968/002/001
- Aldactone 50mg Film Coated Tablets - PA0822/110/002
- Diaclide MR 30mg Modified Release Tablets - PA0577/030/002
- EpiPen 300mcg Solution for Injection in Pre-Filled Pen - PA2010/062/002
- Fostepor Once Weekly 70mg Tablets - PA0577/086/002
- Gaviscon Advance Chewable Tablets - PA0979/011/008
- Gaviscon Advance Oral Suspension 500ml- PA0979/011/001
- Innohep 16,000IU in 0.8ml, Solution for Injection - PA0046/060/014
- Levofloxacin 5mg/ml Solution for Infusion - PA1122/013/001
- Oestrogel Pump-Pack 750mcg/actuation Gel- PA1054/004/001
- Salazopyrin EN Tabs 500mg Gastro Resistant Tablets - PA0822/196/001
Please see the shortages section of the HPRA website for further information.
The HPRA sends weekly updates concerning medicinal product shortages. However, the above webpage will be updated as new information is provided to the HPRA.